전체 프로그램

ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex

Trials 1Status Discontinued

ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex

Trials 1Status Discontinued

AntibodyLimited DatastaleAbbViePhase 1

Pivekimab Sunirine (Pivekimab Sunirine)

Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase1#monoclonal-antibody#MixedPhenotypeAcuteLeukemia+1

Trials 1Status Recruiting

AntibodyLimited DatastaleGenelux CorporationPhase 2

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Ovarian Cancer; Peritoneal Carcinomatosis · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#monoclonal-antibody#PeritonealCarcinomatosis+1

Trials 1Status Active

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

Trials 1Status Active

ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche

Trials 1Status Recruiting

ADCLimited DatastaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche

Trials 1Status Recruiting

AntibodyLimited DatastaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#monoclonal-antibody#AdenocarcinomaoftheStomach+1

Trials 1Status Active

AntibodyLimited DatastaleEmory UniversityPhase 2

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Emory

Trials 1Status Active

AntibodyLimited DatastaleUniversitätsklinikum KölnPhase 2

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases · Cervical Cancer ≥ FIGO IIB and or Lymph

#CervicalCancerFIGOIIBandorLymph#Antibody#Phase2#monoclonal-antibody#CervicalCancerFIGOIIBandorLymphN+1

Trials 1Status Discontinued

AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2

Trials 1Status Recruiting

AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2

Trials 1Status Recruiting

AntibodyLimited DatastaleUniversity Hospital Fattouma Bo…Approved

Preoperative Intra-lesional Bevacizumab Injection in primary pterygium (Preoperative Intra-lesional Bevacizumab Injection in primary pterygium)

Pterygium · Pterygium

#Pterygium#Antibody#Approved#monoclonal-antibody#University

Trials 1Status Active

CGTLimited DatastaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleMustang BioPreclinical

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4

Trials 1Status Discontinued

CGTLimited DatastaleMustang BioPreclinical

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4

Trials 1Status Discontinued

CGTAAVLimited DatastaleMeiraGTx UK II LtdPreclinical

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Preclinical#cell-gene-therapy#CAR-T+2

Trials 1Status Discontinued

CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Prior-HSCT donor-derived CD7 CAR T-cell (Prior-HSCT donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5

Trials 1Status Recruiting

AntibodyLimited DatastaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#monoclonal-antibody#University

Trials 1Status Recruiting

AntibodyLimited DatastaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#monoclonal-antibody#University

Trials 1Status Recruiting

81 / 103 pages

← Previous Next →

다음 갱신 D-2 · 마지막 9월 2일 · 방문 102 / 73,973

Biologic만FDA만

ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex

Trials 1Status Discontinued

ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex

Trials 1Status Discontinued

AntibodyLimited DatastaleAbbViePhase 1

Pivekimab Sunirine (Pivekimab Sunirine)

Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase1#monoclonal-antibody#MixedPhenotypeAcuteLeukemia+1

Trials 1Status Recruiting

AntibodyLimited DatastaleGenelux CorporationPhase 2

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Ovarian Cancer; Peritoneal Carcinomatosis · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#monoclonal-antibody#PeritonealCarcinomatosis+1

Trials 1Status Active

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

Trials 1Status Active

ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche

Trials 1Status Recruiting

ADCLimited DatastaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche

Trials 1Status Recruiting

AntibodyLimited DatastaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#monoclonal-antibody#AdenocarcinomaoftheStomach+1

Trials 1Status Active

AntibodyLimited DatastaleEmory UniversityPhase 2

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Emory

Trials 1Status Active

AntibodyLimited DatastaleUniversitätsklinikum KölnPhase 2

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases · Cervical Cancer ≥ FIGO IIB and or Lymph

#CervicalCancerFIGOIIBandorLymph#Antibody#Phase2#monoclonal-antibody#CervicalCancerFIGOIIBandorLymphN+1

Trials 1Status Discontinued

AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2

Trials 1Status Recruiting

AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2

Trials 1Status Recruiting

AntibodyLimited DatastaleUniversity Hospital Fattouma Bo…Approved

Preoperative Intra-lesional Bevacizumab Injection in primary pterygium (Preoperative Intra-lesional Bevacizumab Injection in primary pterygium)

Pterygium · Pterygium

#Pterygium#Antibody#Approved#monoclonal-antibody#University

Trials 1Status Active

CGTLimited DatastaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleMustang BioPreclinical

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4

Trials 1Status Discontinued

CGTLimited DatastaleMustang BioPreclinical

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4

Trials 1Status Discontinued

CGTAAVLimited DatastaleMeiraGTx UK II LtdPreclinical

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Preclinical#cell-gene-therapy#CAR-T+2

Trials 1Status Discontinued

CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Prior-HSCT donor-derived CD7 CAR T-cell (Prior-HSCT donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5

Trials 1Status Recruiting

AntibodyLimited DatastaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#monoclonal-antibody#University

Trials 1Status Recruiting

AntibodyLimited DatastaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#monoclonal-antibody#University

Trials 1Status Recruiting

81 / 103 pages

← Previous Next →

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Pivekimab Sunirine (Pivekimab Sunirine)

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Preoperative Intra-lesional Bevacizumab Injection in primary pterygium (Preoperative Intra-lesional Bevacizumab Injection in primary pterygium)

Previously treated CAR-T patients (Previously treated CAR-T patients)

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

Prior-HSCT donor-derived CD7 CAR T-cell (Prior-HSCT donor-derived CD7 CAR T-cell)

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

전체 프로그램

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Pivekimab Sunirine (Pivekimab Sunirine)

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Preoperative Intra-lesional Bevacizumab Injection in primary pterygium (Preoperative Intra-lesional Bevacizumab Injection in primary pterygium)

Previously treated CAR-T patients (Previously treated CAR-T patients)

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

Prior-HSCT donor-derived CD7 CAR T-cell (Prior-HSCT donor-derived CD7 CAR T-cell)

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

전체 프로그램

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Pivekimab Sunirine (Pivekimab Sunirine)

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery)

atezolizumab (Tecentriq, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.)

Preoperative Intra-lesional Bevacizumab Injection in primary pterygium (Preoperative Intra-lesional Bevacizumab Injection in primary pterygium)

Previously treated CAR-T patients (Previously treated CAR-T patients)

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

Prior-HSCT donor-derived CD7 CAR T-cell (Prior-HSCT donor-derived CD7 CAR T-cell)

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)